First of all, I think Lilly's Zepbound strategy is brilliant. It should open up a larger market for the company's obesity drug. As James Zervos, chief operating officer with Obesity Action ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX stock is upgraded to hold.

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

NEW YORK — CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.

Eli Lilly has seen US prescriptions for its Zepbound ... but its market value has halved to about $310 billion. Camilla Sylvest, Novo’s head of commercial strategy and corporate affairs and ...

Eli Lilly and ... (May 1st before market open) comes during a period of remarkable expansion in the company's GLP-1 business. Investors will focus on Mounjaro and Zepbound revenue, production ...

without meaningful change in near-term strategy, we continue to see a more difficult path forward," he said. Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar ...

and Henry Meds—accusing them of deceptively marketing and selling compounded versions of its FDA-approved drugs, Mounjaro and Zepbound. Lilly alleges these companies are promoting untested and ...

But the Agars, who live in Minnesota, aren't taking Eli Lilly's Zepbound ... They call it the "gray market." Zepbound and the compounded alternatives have to be sterile for injection, so a ...